Scientists have developed a novel cancer-fighting strategy that tricks tumor cells into manufacturing the very drugs that destroy them, according to early laboratory findings. The technique exploits carbon monoxide naturally produced by cancer cells, using it as a chemical trigger to synthesize powerful therapeutic compounds from inactive precursors delivered to the tumor site. In experiments conducted in vitro, the approach appeared to selectively attack malignant cells while leaving healthy tissue largely unharmed, suggesting a potential pathway toward chemotherapy alternatives with fewer side effects.
The research, still in its preclinical stages, has not yet been tested in animals or human trials, and independent experts caution that significant hurdles remain before clinical application. Key questions include the method's safety profile, the efficiency of drug production within tumors, and whether cancer cells might develop resistance. If the results hold up in further studies, the strategy could represent a meaningful shift in targeted cancer therapy, though researchers emphasize that years of rigorous testing will be required to determine whether the laboratory promise translates into viable treatment for patients.
Independent reporting synthesized from primary wires and global correspondents.